AstraZeneca PLC Files 6-K Report
Ticker: AZN · Form: 6-K · Filed: Dec 4, 2025 · CIK: 901832
| Field | Detail |
|---|---|
| Company | Astrazeneca PLC (AZN) |
| Form Type | 6-K |
| Filed Date | Dec 4, 2025 |
| Risk Level | low |
| Pages | 4 |
| Reading Time | 4 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 6-k, foreign-issuer
Related Tickers: AZN
TL;DR
AZN filed a 6-K, standard foreign issuer report. Nothing new, just compliance.
AI Summary
AstraZeneca PLC filed a Form 6-K on December 4, 2025, reporting its status as a foreign issuer. The filing indicates that AstraZeneca is submitting its reports under Form 20-F, which is standard for foreign private issuers. The company is located at 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, United Kingdom.
Why It Matters
This filing is a routine disclosure for foreign issuers like AstraZeneca, confirming their reporting status and providing updated corporate information to the SEC and investors.
Risk Assessment
Risk Level: low — This is a routine administrative filing by a foreign issuer and does not contain new material financial or operational information.
Key Players & Entities
- AstraZeneca PLC (company) — Filer of the report
- ZENECA GROUP PLC (company) — Former company name
- 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, United Kingdom (location) — Company's business and mail address
FAQ
What type of report is AstraZeneca PLC filing?
AstraZeneca PLC is filing a Form 6-K, which is a Report of Foreign Issuer.
What is the filing date of this report?
The filing date is December 4, 2025.
Which form does AstraZeneca PLC indicate it files annual reports under?
AstraZeneca PLC indicates it files annual reports under Form 20-F.
What is AstraZeneca PLC's primary business classification according to the filing?
AstraZeneca PLC's Standard Industrial Classification is Pharmaceutical Preparations [2834].
What is the company's former name?
The company's former name was ZENECA GROUP PLC, with a date of name change of April 22, 1993.
Filing Stats: 1,113 words · 4 min read · ~4 pages · Grade level 9.8 · Accepted 2025-12-04 13:48:33
Filing Documents
- a3053k.htm (6-K) — 76KB
- 0001654954-25-013678.txt ( ) — 77KB
SIGNATURES
SIGNATURES   Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.     AstraZeneca PLC     Date: 04 December 2025     By: /s/ Matthew Bowden   Name: Matthew Bowden   Title: Company Secretary